Does pegloticase (uricase) cause tremors?

From the Guidelines

Pegloticase may cause tremors as a potential side effect, although the provided evidence does not directly mention this specific side effect 1. If you are experiencing tremors while taking pegloticase, it is recommended to consult your doctor to assess the severity and determine the best course of action.

Important Considerations

• Your doctor may consider adjusting the dose of pegloticase or adding other medications to manage the tremors.
• The typical dose of pegloticase is 8 mg every 2 weeks, and it is usually administered via intravenous infusion.
• In some cases, your doctor may recommend a dose reduction to 4 mg every 2 weeks to minimize side effects.

Key Points to Discuss with Your Doctor

• The severity of your tremors and how they impact your daily life
• The potential benefits and risks of adjusting your pegloticase dose or adding other medications
• The importance of closely monitoring your condition and reporting any changes or concerns to your doctor It is essential to closely monitor your condition and report any changes or concerns to your doctor to ensure safe and effective treatment.

From the Research

Adverse Events Associated with Pegloticase

• The most common adverse events associated with pegloticase include gout flares, infusion reactions, and anaphylaxis 2
• Other reported adverse events include exacerbation of pre-existing congestive heart failure, nephrolithiasis, arthralgia, anemia, dyspnea, headache, muscle spasms, nausea, and pyrexia 3
• Pegloticase has also been associated with thrombocytopenia and severe cardiac adverse effects 4
• A study analyzing reports from the Food and Drug Administration Adverse Event Reporting System (FAERS) database found potential signals for pegloticase-associated cardiovascular events, infusion-related reactions, gout flares, and anaphylaxis 5

Neurological Adverse Events

• There is no direct evidence in the provided studies that pegloticase causes tremors
• However, muscle spasms were reported as an adverse event in one of the studies 3

Overall Safety Profile

• Pegloticase has been found to have a higher risk of adverse events, including serious adverse events 6, 4
• The long-term effects of pegloticase are unknown, and its use has been associated with the development of anti-pegloticase antibodies in approximately 90% of patients 4